stockrow
Friday 6 November 2026
Export AZR’s income statement to Excel — free account
Azora Therapeutics, Inc.
- EPS
- −150.0%
- Free cash flow
- −263.7%
Quarter to June 2026, against a year earlier
3.82
0.23
−5.68%
Follow AZR
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | 0 | (1) | (12) | (9) | (11) | (20) | (11) | (7) | (13) | (8) | (58) | +38.7% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | 0 | (1) | (12) | (9) | (11) | (19) | (11) | (7) | (13) | (8) | (58) | +38.7% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (80.61) | (218.19) | (1,525.00) | (543.75) | (543.75) | (650.00) | (318.75) | (90.00) | (68.00) | (11.93) | (16.54) | (19.1%) | ||||||
| Cash flow | (52.77) | (95.17) | (328.74) | (401.18) | (383.58) | (402.34) | (278.95) | (119.42) | (35.66) | (9.71) | (2.41) | (17.1%) | ||||||
| Capex | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (2.18) | 0.00 | 0.00 | 0.00 | 0.22 | 0.00 | n/m | ||||||
| Free cash flow | (52.77) | (95.17) | (328.74) | (401.18) | (383.58) | (404.51) | (278.95) | (119.42) | (35.66) | (9.49) | (2.41) | (17.4%) | ||||||
| Book value | (19.90) | (191.85) | 584.38 | 451.94 | 200.31 | 118.11 | 81.71 | 71.64 | 20.96 | 7.89 | (8.30) | n/m | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | +71.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | 0 | 0 | (2) | (6) | (8) | (12) | (11) | (7) | (7) | (6) | (11) | +42.1% | |||||
| Capex | — | — | — | — | — | 0 | — | — | — | 0 | 0 | n/m | ||||||
| Free cash flow | 0 | 0 | (2) | (6) | (8) | (12) | (11) | (7) | (7) | (6) | (11) | +41.8% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 0 | (1) | 4 | 7 | 4 | 4 | 3 | 3 | 3 | 5 | 24 | n/m | |||||
| Net debt | 0 | 0 | (4) | (7) | (4) | (6) | (4) | (3) | (4) | (6) | (29) | +59.5% | ||||||
| Shareholders’ equity | 0 | (1) | 4 | 7 | 4 | 4 | 3 | 4 | 4 | 5 | (38) | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (451.83) | (1,225.27) | (491.42) | (138.81) | (165.41) | (299.59) | (192.79) | (97.87) | (269.87) | (136.16) | (322.10) | +315.7 pt | |||||
| ROIC | 0.00 | 0.00 | (763.06) | (1,417.62) | 0.00 | 0.00 | 0.00 | (342.64) | (1,630.29) | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | 76.32 | 206.97 | (675.52) | (148.36) | (195.80) | (518.38) | (375.32) | (139.22) | (323.80) | (170.73) | 352.60 | (247.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | 3 | 6 | 4 | 9 | 21 | 4 | 7 | 7 | 6 | — | +9.1% | |||||
| Revenue/emp, $m | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Azora Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PASG Passage Bio, Inc. | $11.1M | — (loss-making) | — | — | n/m | −59.81% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| LSTA Lisata Therapeutics, Inc. | $10.7M | — (loss-making) | — (loss-making) | −98.30% (below 0%: shrinking) | n/m | +33.04% (above 0%: growing) | 100.00% | 0.00% | Compare |
| GDTC CytoMed Therapeutics Limited | $10.4M | — (loss-making) | — (loss-making) | — | n/m | −27.39% (below 0%: shrinking) | 0.00% | — | Compare |
| BIVI BioVie Inc. | $10.3M | — (loss-making) | — | — | n/m | +26.50% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PTN Palatin Technologies, Inc. | $10.2M | 12.2× | 0.2× | −14.06% (below 0%: shrinking) | n/m | +34.21% (above 0%: growing) | 100.00% | (1,469.35%) | Compare |
| INTS Intensity Therapeutics Inc. | $10.1M | — (loss-making) | — | — | n/m | +4.72% (above 0%: growing) | 0.00% | 0.00% | Compare |
| AZR Azora Therapeutics, Inc. | $9.7M | — (loss-making) | — | — | n/m | −263.66% (below 0%: shrinking) | 0.00% | 0.00% | |
| GTBP GT Biopharma, Inc. | $9.4M | 0.8× | — | −100.00% (below 0%: shrinking) | n/m | −41.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PHIO Phio Pharmaceuticals Corp. | $9.3M | — (loss-making) | — (loss-making) | −8.70% (below 0%: shrinking) | n/m | −58.67% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $10.2M | — | — | −56.18% | — | −11.33% | 0.00% | 0.00% |
Pay and ownership Proxy statement filed 24 August 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 890.65k | 600.17k | 4.09 |
| 2024 | 976.34k | 823.53k | 18.79 |
| 2023 | 801.62k | 575.60k | 34.60 |
Ownership
Directors and executive officers, together
8.00%
Matthew Davidson, Ph.D. (Chief Development Officer and Director)
14.80%
Coastlands Capital LP
14.20%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement